Markets:

Overview

News

Currencies

International

Treasuries

23andMe Holding Co. - Common Stock (NQ:ME)

0.6063 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 23andMe Holding Co. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023

March 14, 2023

Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented

From 23andMe Holding Co.

Via GlobeNewswire

AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023 ↗

March 09, 2023

They've been using machine learning for years, and now they might do even more.

Via The Motley Fool

New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare

March 09, 2023

From 23andMe Holding Co.

Via GlobeNewswire

2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise ↗

March 02, 2023

There's nothing better than getting a bargain that'll pay off for years.

Via The Motley Fool

This Genetics Stock Could Have Massive Long-Term Potential ↗

February 10, 2023

This healthcare company isn't without risk but is doing a good job executing on its vision.

Via The Motley Fool

A Preview Of 23andMe Holding's Earnings ↗

February 07, 2023

Via Benzinga

2 High-Growth Stocks That Could Double Your Money in 5 Years or Less ↗

February 28, 2023

Both are likely to double quite soon, and they aren't even that risky.

Via The Motley Fool

23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies

February 28, 2023

The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and...

From 23andMe Holding Co.

Via GlobeNewswire

23andMe to Present at Upcoming Investor Conferences

February 22, 2023

From 23andMe Holding Co.

Via GlobeNewswire

MGM Resorts, Madison Square Garden Entertainment, Cardiovascular Systems And Other Big Stocks Moving Higher On Thursday ↗

February 09, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 09, 2023

Gainers Hempacco Co., Inc. (NASDAQ: HPCO) rose 296% to $2.99 after declining 6% on Wednesday.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 08, 2023

Via Benzinga

23andMe Reports FY2023 Third Quarter Financial Results

February 08, 2023

From 23andMe Holding Co.

Via GlobeNewswire

7 Former SPACs I Still Own (And What I Think Now) ↗

January 28, 2023

Remember the SPAC boom? Here are seven products of that time that are still in my portfolio.

Via The Motley Fool

23andMe to Report FY2023 Third Quarter Financial Results

January 26, 2023

From 23andMe Holding Co.

Via GlobeNewswire

3 Penny Stocks That Could Make You Filthy Rich ↗

January 25, 2023

These low-priced equities could deliver enormous returns for risk-tolerant shareholders.

Via The Motley Fool

My 4 Worst-Performing Stocks and What I Think Now ↗

January 10, 2023

These stocks are all down 70% or more from what I paid.

Via The Motley Fool

Guardant Health, Novavax And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗

December 16, 2022

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

January 06, 2023

During Friday's trading, 71 companies set new 52-week lows.

Via Benzinga

25 Meme Stocks to Sell Before They Die ↗

December 15, 2022

Wondering what the best meme stocks to sell for 2023 are? Here are the top picks that investors should offload and avoid.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday ↗

January 05, 2023

On Thursday, 63 companies set new 52-week lows.

Via Benzinga

The Worst Investment Decision I Made in 2022 ↗

December 10, 2022

The stock market has had a terrible year, and here are some moves we wish we could do over.

Via The Motley Fool

Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session ↗

December 05, 2022

Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share.

Via Benzinga

23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season

December 01, 2022

From 23andMe Holding Co.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022 ↗

November 29, 2022

Via Benzinga

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

November 10, 2022

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.

Via TheNewswire.com

The NIH Has Given BioRestorative Therapies A Stamp Of Approval ↗

November 09, 2022

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.

Via Benzinga

23andMe Reports FY2023 Second Quarter Financial Results

November 07, 2022

From 23andMe Holding Co.

Via GlobeNewswire

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting

November 07, 2022

The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity

From 23andMe Holding Co.

Via GlobeNewswire

A Preview Of 23andMe Holding's Earnings ↗

November 04, 2022

23andMe Holding (NASDAQ:ME) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that 23andMe Holding...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.